InsiderTrades.com logo

ABIO Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 30.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

ARCA biopharma Insider Trading History Chart

This chart shows the insider buying and selling history at ARCA biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ARCA biopharma Share Price & Price History

Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 08/30/2024 09:53 PM ET

This chart shows the closing price history over time for ABIO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

ARCA biopharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2024Henderson Group Plc JanusMajor ShareholderBuy40$421.92$16,876.8014,702View SEC Filing Icon  
7/24/2024Henderson Group Plc JanusMajor ShareholderBuy1,318$460.80$607,334.4014,452View SEC Filing Icon  
7/10/2024Henderson Group Plc JanusMajor ShareholderBuy385$498.24$191,822.4012,477View SEC Filing Icon  
7/8/2024Henderson Group Plc JanusMajor ShareholderBuy329$498.24$163,920.9611,974View SEC Filing Icon  
7/5/2024Henderson Group Plc JanusMajor ShareholderBuy196$493.92$96,808.3211,645View SEC Filing Icon  
7/3/2024Henderson Group Plc JanusMajor ShareholderBuy1,153$511.20$589,413.6011,448View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for ARCA biopharma (NASDAQ:ABIO)

56.44% of ARCA biopharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ABIO by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

ARCA biopharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
9/16/2024Cubist Systematic Strategies LLC27,779$0.11M0.0%N/A0.191%Search for SEC Filing on Google Icon
8/16/2024Perceptive Advisors LLC15,507,760$59.40M1.4%N/A106.898%Search for SEC Filing on Google Icon
8/16/2024Driehaus Capital Management LLC3,846,150$14.73M0.1%N/A26.512%Search for SEC Filing on Google Icon
8/15/2024Affinity Asset Advisors LLC72,484$0.28M0.0%N/A0.500%Search for SEC Filing on Google Icon
8/14/2024Cubist Systematic Strategies LLC27,779$0.11M0.0%N/A0.191%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC73,099$0.28M0.0%+11.3%0.504%Search for SEC Filing on Google Icon
8/7/2024Cowen AND Company LLC700,000$2.68M0.1%N/A4.825%Search for SEC Filing on Google Icon
2/20/2024Cable Car Capital LLC4,000,452$6.80M7.6%N/A27.589%Search for SEC Filing on Google Icon
1/31/2024abrdn plc32,461$55K0.0%N/A0.000%Search for SEC Filing on Google Icon
11/14/2023Newtyn Management LLC300,000$0.60M0.1%-4.2%0.000%Search for SEC Filing on Google Icon
4/14/2023BML Capital Management LLC706,930$1.41M1.2%-17.6%0.000%Search for SEC Filing on Google Icon
2/13/2023BML Capital Management LLC858,256$2.03M1.9%N/A5.956%Search for SEC Filing on Google Icon
2/10/2023Murchinson Ltd.50,593$0.12M0.0%N/A0.351%Search for SEC Filing on Google Icon
11/7/2022Virtu Financial LLC14,221$29K0.0%N/A0.099%Search for SEC Filing on Google Icon
7/27/2022Bailard Inc.35,000$87K0.0%N/A0.243%Search for SEC Filing on Google Icon
4/26/2022Marquette Asset Management LLC17,318$40K0.0%N/A0.120%Search for SEC Filing on Google Icon
2/10/2022Acadian Asset Management LLC57,822$0.12M0.0%N/A0.401%Search for SEC Filing on Google Icon
11/15/2021GSA Capital Partners LLP441,945$1.31M0.1%+238.9%3.067%Search for SEC Filing on Google Icon
11/15/2021Minerva Advisors LLC10,000$30K0.0%N/A0.069%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.268,394$0.80M0.0%-1.8%1.863%Search for SEC Filing on Google Icon
8/16/2021State Street Corp69,037$0.24M0.0%N/A0.479%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
ARCA biopharma logo
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Read More on ARCA biopharma

Today's Range

Now: N/A

50 Day Range

MA: $384.99
Low: $2.40
High: $599.04

52 Week Range

Now: N/A

Volume

290,800 shs

Average Volume

607,995 shs

Market Capitalization

$34.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91

Who are the company insiders with the largest holdings of ARCA biopharma?

ARCA biopharma's top insider investors include:
  1. Henderson Group Plc Janus (Major Shareholder)
Learn More about top insider investors at ARCA biopharma.